Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma
Open Access
- 1 January 2020
- journal article
- letter
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 16 (3), 497-498
- https://doi.org/10.3988/jcn.2020.16.3.497
Abstract
Shin JH, et al. J Clin Neurol. 2020 Jul;16(3):497-498. https://doi.org/10.3988/jcn.2020.16.3.497Keywords
This publication has 9 references indexed in Scilit:
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literatureJournal for ImmunoTherapy of Cancer, 2019
- Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemiaAnnals of Clinical and Translational Neurology, 2018
- Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic CancerJournal of Clinical Neurology, 2018
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) AntibodiesJAMA Neurology, 2017
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitorsEuropean Journal of Cancer, 2017
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature reviewNeuromuscular Disorders, 2017
- Pembrolizumab-induced myasthenia gravis: A fatal case reportJournal of Oncology Pharmacy Practice, 2017
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Autoimmune mechanisms in myasthenia gravisCurrent Opinion in Neurology, 2012